Profile data is unavailable for this security.
About the company
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
- Revenue in SEK (TTM)12.85m
- Net income in SEK-19.50m
- Incorporated2014
- Employees2.00
- LocationElicera Therapeutics ABWorld Trade Center GoteborgMassans gata 10, van 7GOETEBORG 412 51SwedenSWE
- Websitehttps://www.elicera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
XP Chemistries AB | 443.13k | -7.84m | 15.32m | 2.00 | -- | 0.6427 | -- | 34.58 | -0.2479 | -0.2479 | 0.0098 | 0.2552 | 0.0164 | 3.25 | 18.68 | 221,565.00 | -29.04 | -- | -30.83 | -- | -1,116.68 | -- | -1,769.29 | -- | 4.72 | -- | 0.00 | -- | -37.14 | -- | -1.55 | -- | -- | -- |
Cyxone AB | 0.00 | -21.66m | 21.81m | 1.00 | -- | 0.6358 | -- | -- | -0.1747 | -0.1747 | 0.00 | 0.1589 | 0.00 | -- | -- | 0.00 | -50.57 | -66.19 | -57.08 | -72.35 | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -- | -- | 45.87 | -- | -13.31 | -- |
Redwood Pharma AB | 0.00 | -13.60m | 22.61m | 1.00 | -- | 0.3344 | -- | -- | -5.87 | -5.87 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -106.53 | -95.03 | -121.24 | -123.04 | -- | -- | -- | -- | -- | -19.12 | 0.00 | -- | -- | -- | -8.78 | -- | -5.11 | -- |
Lipigon Pharmaceuticals AB | 16.41m | -12.71m | 35.15m | -- | -- | 1.64 | -- | 2.14 | -0.2459 | -0.2459 | 0.2138 | 0.1694 | 1.07 | -- | 21.49 | -- | -83.21 | -314.67 | -137.73 | -426.49 | -- | -- | -77.44 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
Oncozenge AB | 0.00 | -14.22m | 43.05m | -- | -- | 2.65 | -- | -- | -1.21 | -1.21 | 0.00 | 1.39 | 0.00 | -- | -- | -- | -58.23 | -- | -61.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
Elicera Therapeutics AB | 12.85m | -19.50m | 46.15m | 2.00 | -- | 1.46 | -- | 3.59 | -0.9726 | -0.9726 | 0.6416 | 0.901 | 0.3015 | -- | 11.43 | 6,426,955.00 | -45.75 | -40.06 | -62.75 | -49.74 | -- | -- | -151.72 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
Lipidor AB | 87.00k | -11.59m | 51.32m | -- | -- | -- | -- | 589.93 | -0.1049 | -0.1049 | 0.0008 | -0.0817 | 0.0122 | -- | 0.19 | -- | -162.65 | -59.41 | -- | -75.10 | -- | -- | -13,322.99 | -643.36 | -- | -- | -- | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
Ziccum AB | 6.64m | -20.50m | 84.55m | 9.00 | -- | 6.45 | -- | 12.74 | -1.46 | -1.46 | 0.4721 | 0.8534 | 0.2696 | -- | 22.01 | 829,375.00 | -83.29 | -68.51 | -106.42 | -76.47 | -- | -- | -308.94 | -2,598.03 | -- | -- | 0.0516 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
Odi Pharma AB (publ) | 14.80m | -1.67m | 105.78m | -- | -- | 30.31 | -- | 7.15 | -0.1097 | -0.1097 | 0.9727 | 0.2293 | 1.36 | 18.13 | 3.94 | -- | -15.36 | -- | -39.25 | -- | -25.26 | -- | -11.27 | -- | 1.26 | -2.31 | 0.00 | -- | -55.44 | -- | 4.67 | -- | -- | -- |
StenoCare A/S | 6.25m | -25.60m | 110.30m | 9.00 | -- | 3.23 | -- | 17.65 | -1.13 | -1.13 | 0.2674 | 1.22 | 0.1285 | -- | 2.94 | -- | -52.62 | -28.16 | -70.34 | -35.47 | -- | -- | -409.55 | -371.06 | 1.04 | -5.56 | 0.2362 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
Isofol Medical AB (publ) | 0.00 | -31.16m | 111.12m | 4.00 | -- | 0.9838 | -- | -- | -0.1964 | -0.1964 | 0.00 | 0.6993 | 0.00 | -- | -- | 0.00 | -20.49 | -66.73 | -24.10 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
Pila Pharma AB | 1.46m | -9.93m | 115.40m | 1.00 | -- | 17.32 | -- | 78.88 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
ExpreS2ion Biotech Holding AB | 7.77m | -77.95m | 124.52m | 18.00 | -- | 1.29 | -- | 16.03 | -1.33 | -1.33 | 0.129 | 0.8696 | 0.0821 | -- | 4.87 | 298,730.80 | -82.36 | -63.54 | -113.92 | -75.88 | -132.91 | -1.94 | -1,003.55 | -524.31 | -- | -- | 0.0055 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |